REG - Faron Pharma. Oy - Board Change

Faron Pharmaceuticals OyAnnouncement

24/03/2023 13:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230324:nRSX1996Ua&default-theme=true

RNS Number : 1996U  Faron Pharmaceuticals Oy  24 March 2023

Faron Pharmaceuticals Oy

("Faron" or the "Company")

 

 

Board Change

 

 

Company announcement, March 24, 2023 at 15.35 PM (EET) / 13.35 PM (GMT) /
09.35 AM (EDT)

 

TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Oy (AIM: FARN, First
North: FARON), a clinical stage biopharmaceutical company focused on tackling
difficult-to-treat cancers, is pleased to announce the appointment of Mr.
Tuomo Pätsi as a Non-Executive Director of the Company following the passing
of all resolutions put to shareholders of the Company at the Annual General
Meeting held earlier today. In addition, Dr. Gregory B. Brown has today
stepped down from his position as a Non-Executive Director of the Company.

 

"I am pleased to welcome Mr Pätsi to the Faron Board," said Dr. Frank
Armstrong, Chairman of the Board of Faron Pharmaceuticals. "He brings
extensive experience of the commercialization and launch of new oncology
products with leading cancer companies, and his expertise will be valuable as
the Company continues the development of bexmarilimab. I'd also like to thank
Dr. Brown for his service to the Faron Board."

 

Mr. Pätsi was the President of the EMEA region and Worldwide Markets for
Celgene Corporation, a global pharmaceutical company and currently wholly
owned subsidiary of Bristol Myers Squibb, engaged primarily in the discovery,
development and commercialization of therapies for the treatment of cancer. He
is an experienced biotech and pharmaceutical executive who was until recently
the Executive Vice President for Seagen Inc., a US-based cancer-focused
biotechnology company.

 

"I am looking forward to joining the Board of Faron at this exciting time,"
said Mr Pätsi. "Bexmarilimab with its innovative mechanism of action and
clinical data so far holds great promise in multiple cancer indications where
better treatments are desperately needed."

 

Mr. Pätsi has over 30 years' experience working in biotech and
pharmaceuticals, with more than 10 years working at Celgene in various senior
management roles, including as President of European and International
Operations and President of the EMEA region and Worldwide Markets. Prior to
this, he served as Vice President of Europe for Human Genome Science, a
specialty pharma organization in Europe. Earlier in his career, he held roles
of increasing responsibility in pharmaceutical companies, including more than
ten years at Amgen Inc.  Mr. Pätsi began his career as a Biomedical Research
Scientist in Finland. He is a registered pharmacist and holds an MSc in
pharmacology from the School of Pharmacy, Helsinki University.

 

Additional Disclosures

 

The following information regarding the appointment of Tuomo Tapani Pätsi
(aged 58), is disclosed under Schedule 2(g) of the AIM Rules for Companies and
Nasdaq First North Growth Market Rulebook.

 

 Current positions, directorships and/or partnerships:  Former positions, directorships and/or partnerships (within the last five

                                                      years):

                                                        Celgene
                                                        Celgene ApS
                                                        Celgene BV
                                                        Celgene Distribution BV
                                                        Celgene EngMab GmbH
                                                        Celgene Europe BV
                                                        Celgene Europe Limited
                                                        Celgene Global Holdings Sàrl
                                                        Celgene GmbH
                                                        Celgene International II Sàrl
                                                        Celgene International III Sàrl
                                                        Celgene International Sàrl
                                                        Celgene Limited
                                                        Celgene Logisitics Sarl
                                                        Celgene Logistics Sàrl
                                                        Celgene Management Sàrl
                                                        Celgene Netherlands BV
                                                        Celgene Netherlands II BV
                                                        Celgene Netherlands Investment BV
                                                        Celgene R&D Sàrl
                                                        Celgene Receptos Limited
                                                        Celgene Receptos Sàrl
                                                        Celgene Research SL
                                                        Celgene SL
                                                        Celgene Spółka SOO
                                                        Celgene sro
                                                        Celgene Switzerland Sàrl
                                                        Celgene Tri Sàrl
                                                        EngMab Sàrl
                                                        Interpharma
                                                        Juno Therapeutics GmbH

 

Mr. Pätsi does not have any beneficial interest in the ordinary shares or
options over the ordinary shares of the Company.

 

Save as set out above, no further information regarding Mr. Pätsi is required
to be disclosed pursuant to the AIM Rules for Companies or Nasdaq First North
Growth Market Rulebook.

 

For more information please contact:

 

Media Contact

Faron Pharmaceuticals

Faron Pharmaceuticals

Jennifer C. Smith-Parker

Head of Communications

Jennifer.Smith-Parker@faron.com

 

Investor Contact

Faron Pharmaceuticals

Julia Balanova

VP, Investor Relations

julia.balanova@faron.com (mailto:julia.balanova@faron.com)

investor.relations@faron.com (mailto:investor.relations@faron.com)

Phone: +1 (917) 306-6096

 

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

 

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

 

Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Lindsey Neville
faron@consilium-comms.com (mailto:faron@consilium-comms.com)

Phone: +44 (0)20 3709 5700

 

About Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON) together with its
subsidiaries, is a clinical stage biopharmaceutical group focused on building
the future of immunotherapy by harnessing the power of the immune system to
tackle cancer and inflammation. Bexmarilimab, a novel anti-CLEVER-1 humanized
antibody, is its investigative precision immunotherapy with the potential to
provide permanent immune stimulation for difficult-to-treat cancers through
targeting myeloid function. Currently in Phase I/II clinical development as a
potential therapy for patients with hematological cancers and untreatable
solid tumors, bexmarilimab has potential as a single-agent therapy or in
combination with other standard treatments including immune checkpoint
molecules. In terms of other pipeline assets, Traumakine® is an
investigational intravenous (IV) interferon beta-1a therapy for the treatment
of hyperinflammatory conditions. Faron is headquartered in Turku, Finland.
Further information is available at www.faron.com (http://www.faron.com/) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAPPUBUWUPWGWC